Huntington’s disease research news. In plain language. Written by scientists. For the global HD community.
Just like it is difficult to predict exactly when a storm will hit, predicting when Huntington’s disease symptoms will arise for any particular person is hard to do. However, new research suggests that tiny changes in the on switch of the Huntington’s gene affect symptom onset – and may provide important information in the search for Huntington’s therapies.
Auspex Pharmaceuticals just announced the results of two clinical trials known as 'First-HD' and 'Arc-HD'. These trials were designed to test a modified version of the approved Huntington's disease drug tetrabenazine, which reduces unwanted movements. The results reveal that Auspex's drug has some advantages compared to tetrabenazine for treating excessive movements in HD.
A new clinical trial just announced for 2015 aims to test a “huntingtin lowering” therapy, called an antisense oligonucleotide (ASO), that attacks mutant huntingtin directly. We’re extremely excited—it’s the first-ever human HD trial to fight HD at the root of the problem, and has shown great promise in animal models. What’s the scoop?
CREST-E, the largest clinical trial of the dietary supplement creatine, has been terminated early because an early analysis of the results to date showed there was no realistic chance it could show positive results. This provides compelling evidence that creatine doesn't slow down progression in Huntington's disease patients.
Our final report from the European HD Network meeting. For the first time, video of many presentations, including our 'EuroBuzz' sessions will be made available online shortly.
Here's Ed and Jeff's live Twitter report from the second day of the EHDN 2014 meeting. Our final report will be tomorrow, and we'll be uploading video of our onstage roundup sessions soon.
Join Jeff and Ed as we tweet live from the 2014 European Huntington's Disease Network meeting in Barcelona! Exciting science ahead!
The largest ever therapeutic trial for Huntington's disease was halted early this week because an analysis of the results to date showed that it was very unlikely to show positive results. The study, called 2CARE, was designed to test whether a treatment called coenzyme Q10 could slow the progression of HD.
The symptoms of HD are caused by damage to the brain, but not all parts of the brain are affected equally. This raises an important question - if we had a treatment that could help only a small part of the brain, which part would we pick? A new mouse study from William Yang, at UCLA, attempts to answer this question.